Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

Stock Information for BiondVax Pharmaceuticals Ltd.

Loading

Please wait while we load your information from QuoteMedia.